KALA BIO, Inc.
KALA
$9.31
$0.536.04%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 17.84M | 17.51M | 18.34M | 18.76M | 19.31M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 40.55M | 39.31M | 40.43M | 40.32M | 41.25M |
Operating Income | -40.55M | -39.31M | -40.43M | -40.32M | -41.25M |
Income Before Tax | -37.23M | -35.65M | -38.51M | -38.96M | -38.72M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -37.23 | -35.65 | -38.51 | -38.96 | -38.72 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -37.23M | -35.65M | -38.51M | -38.96M | -38.72M |
EBIT | -40.55M | -39.31M | -40.43M | -40.32M | -41.25M |
EBITDA | -40.28M | -39.05M | -40.18M | -40.06M | -40.98M |
EPS Basic | -6.80 | -8.25 | -11.03 | -12.47 | -13.95 |
Normalized Basic EPS | -4.18 | -5.10 | -6.81 | -6.86 | -8.27 |
EPS Diluted | -6.80 | -8.25 | -11.03 | -12.47 | -13.95 |
Normalized Diluted EPS | -4.18 | -5.10 | -6.81 | -6.86 | -8.27 |
Average Basic Shares Outstanding | 22.18M | 18.70M | 15.17M | 13.18M | 11.11M |
Average Diluted Shares Outstanding | 22.18M | 18.70M | 15.17M | 13.18M | 11.11M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |